|
|
|
|
AbraxaneCancer Consultants (press release), Researchers affiliated with the US Oncology Research Network recently reported that the addition of dose-dense Abraxane (ABI-007) in the dose-dense AC ... NCCN Adds Abraxane™ to Guidelines for Treatment of Advanced ... Dec 21, 2005 Cancer Consultants (press release), The National Comprehensive Cancer Network (NCCN) has recently added the chemotherapy agent Abraxane™ (albumin-bound paclitaxel) to the list of preferred ... Pilot Study Shows Abraxane Safe and Effective in Sequence with ... Dec 13, 2005 DG News Each molecule of Abraxane (ABI-007) measures 130 nm in diameter, which permits it to cross blood vessel membranes, pass through the interstitium (the area ... American Bioscience Inc. Names Barry Flannelly, Pharm.D, MBA, as ... Dec 21, 2005 Yahoo! News (press release) ...of global sales and marketing of proprietary oncology drugs make him ideally suited to lead our sales and marketing efforts for ABRAXANE® worldwide," said ... American Bioscience Inc. Names Barry Flannelly, Pharm.D, MBA, as ... Dec 21, 2005 PR Newswire (press release), ...for Femara(R) at Novartis Oncology and Vice President Oncology Marketing for Taxotere(R) at Sanofi-Aventis to Lead Global Rollout of ABRAXANE(R) - SCHAUMBURG ... Breast cancer therapeutics benefits from cytotoxic alternatives Dec 23, 2005 In-PharmaTechnologist.com, Much needed therapy will be in the form of American BioScience's Abraxane, a reformulated paclitaxel currently in preregistration. ... 2005 Gave Nanotech Investors Plenty to Chew On Jan 6, 2006 Motley Fool Partners' (Nasdaq: APPX) (soon to be renamed Abraxis BioScience) stock jumped 50% on news that it had received FDA approval for its breast cancer drug, Abraxane ... American Pharmaceutical Partners Receives FDA Approval for ... Dec 14, 2005 PR Newswire (press release), ...the proprietary division of APP, is devoted entirely to developing and promoting innovative, next-generation cancer therapies such as ABRAXANE(R), recently ... Sir Richard Sykes, Former Glaxo Wellcome Chairman, CEO and ... Dec 20, 2005 Yahoo! News (press release) ...proprietary division of APP, is devoted entirely to developing and promoting innovative, next-generation cancer therapies such as ABRAXANE®, recently launched ... Panel Revises Breast Cancer Treatment Guidelines Dec 13, 2005 ABC News ..."It's a very rapidly evolving field.". The NCCN panel also added three new drugs to the list of treatments for metastatic disease: Taxol, Avastin and Abraxane. ... |
|
Home Copyright phasechange.org 2006. All Rights Reserved. |